Cryo-Cell International, Inc. (CCEL)

Cryo-Cell International's stock price has experienced a significant decline over the past six months and year. Between November 7, 2024, and November 6, 2025, the share price decreased by 48.39%. Over the last year, the stock showed a 53.49% decrease. Key events impacting the stock include Maxim Group downgrading Cryo-Cell International from "Buy" to "Hold" in October 2025, the company reporting its fiscal third-quarter 2025 financial results on October 15, 2025, providing a dividend update on August 14, 2025, and reporting its fiscal second-quarter 2025 financial results on July 15, 2025. As of November 26, 2025, the company's market capitalization was $32.7 million, representing a 53.55% decrease in one year.

Cryo-Cell International tracks seasonality to identify patterns in its monthly returns, which can be used to inform investment decisions. However, the specific details or patterns of demand seasonality for Cryo-Cell International's products and services are not explicitly provided in the available information.

Cryo-Cell International, Inc. specializes in cellular processing and cryogenic storage, primarily focusing on the cryopreservation of umbilical cord blood and tissue. Founded in 1989, it was the first private cord blood bank in the United States. The company operates within the Healthcare sector, specifically in the Medical Care Facilities and Healthcare Providers & Services industries. Its services include private cord blood banking, cord tissue banking, adipose tissue banking, manufacturing and sale of PrepaCyte CB Units, public cord blood banking, and research and development.

Headquartered in Oldsmar, Florida, Cryo-Cell International serves families across 87 countries, including Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, India, Mexico, Nicaragua, Pakistan, Panama, Peru, Republica Dominicana, Venezuela, and the United States.

Cryo-Cell International maintains a strong reputation as a market leader in the field of cryopreservation and regenerative medicine. Being the world's first private cord blood bank, the company has established significant brand recognition both in the U.S. and internationally. No specific events negatively impacting Cryo-Cell International's brand reputation in the past year were found in the provided search results.

Cryo-Cell International, Inc. has a diverse ownership structure, including institutional and individual investors. The company has 27 institutional owners and shareholders holding a total of 1,046,343 shares. Major institutional owners include Hamilton Lane Advisors Llc, SFI Advisors, LLC, and Vanguard Group Inc. Major individual insider owners include Ki Yong Choi, David Portnoy, and George Gaines. Insiders collectively hold 115.43% of Cryo-Cell International's stock, while institutional shareholders own 12.27%. In the past three months, insiders have bought more company stock than they have sold.